Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis

Anakinra, a human recombinant IL-1 receptor antagonist, is approved for the treatment of RA. In this study, 12 patients received the placebo plus MTX treatment, 38 patients received Anakinra combined with MTX treatment. Compared with the placebo plus MTX group, serum levels of IL-17, IFN-γ, IL-21 and IL-1β significantly decreased, the percentages of Th17 cells and Th1 cells were lower and the percentage of Treg cells was higher after receiving Anakinra combined with MTX treatment. The observed regulatory immune responses collectively correlated with clinical improvement in treated patients. A substantial response, ACR 20 at 24 w were consistent with those at 12 w, 16 w and 20 w, and was accompanied by a marked improvement in RA related laboratory parameters. The study reveals that the combination of Anakinra and MTX is safe and well tolerated, which induces regulatory immune responses and significantly provides greater clinical benefit than the placebo plus MTX group.

► We observed the immunological changes after Anakinra treatment in RA patients. ► Serum levels of IL-17, IFN-γ, IL-21 and IL-1β significantly decreased. ► The percentages of Th17, Th1 were lower and the percentage of Treg was higher. ► Significant reduction in swollen, tender joint counts and other clinical variables.